Аннотация:Rosiglitazone, a member of the thiazolidinediones, is a well-established oral antidiabetic agent. It reduces plasma glucose levels and glucose production, increases glucose clearance, and significantly improves insulin sensitivity, pancreatic β-cell function, and cardiovascular risk factors (1). In addition to the potential risk of liver toxicity, thiazolidinediones can cause fluid retention, which can exacerbate congestive heart failure (2). Hematologic effects reported in clinical trials include only small decreases in Hb and hematocrit. A recent report described rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil (3). We report a case of mild, reversible pancytopenia during treatment with rosiglitazone for type …
Ключевые слова:Peroxisome Proliferator-Activated Receptors, Metabolism, Diabetes, and Cancer, Hyperglycemia and glycemic control in critically ill and hospitalized patients
